How long should sponsor-specific essential documents be retained?

• A. Until 2 years after the last approval of a marketing application in an ICH region
• B. Until there are no pending or contemplated marketing applications in an ICH region or at least 2 years after discontinuation of clinical development
• C. Until the trial ends
• D. Indefinitely

Answer: (B)

Retaining sponsor-specific essential documents is tied to the funding and oversight of marketing authorization. The idea is to keep these documents long enough to support any future regulatory reviews or inquiries, even after a trial ends or development changes course. The best approach is to keep them until there are no pending or contemplated marketing applications in an ICH region, or at least two years after discontinuation of clinical development, whichever longer. This ensures that if a marketing submission is pursued later, regulators have access to the necessary trial information, and researchers can address safety queries that may arise after development ends. Shorter timelines, like only until the trial ends, risk losing needed records for regulatory review; while keeping them indefinitely isn’t required by GCP.